|Bid||2,156.00 x N/A|
|Ask||2,160.00 x N/A|
|Day's range||2,153.00 - 2,226.00|
|52-week range||2,153.00 - 3,948.00|
|Beta (5Y monthly)||0.87|
|PE ratio (TTM)||55.22|
|Earnings date||28 Oct 2021 - 01 Nov 2021|
|Forward dividend & yield||27.00 (1.09%)|
|Ex-dividend date||29 Sept 2021|
|1y target est||4,472.70|
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.